Lapatinib side effects: what 15,427 FDA adverse event reports show
Drug class
Kinase inhibitor
Who reports
15,427 reports · 68% serious · 2,475 with death outcome · 95% female
Used for
Lapatinib tablets are kinase inhibitor indicated in combination with: ( 1 ) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy, including an anthracycline, a taxane, and trastuzumab.
What it is
Lapatinib is a small molecule and a member of the 4-anilinoquinazoline class of kinase inhibitors. It is present as the ditosylate salt, with chemical name N -(3 chloro-4-[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine bis(4-methylbenzenesulfonate).
Boxed warning
HEPATOTOXICITY Hepatotoxicity has been observed in clinical trials and postmarketing experience. The hepatotoxicity may be severe and deaths have been reported. Causality of the deaths is uncertain [see Warnings and Precautions (5.2)]. WARNING: HEPATOTOXICITY See full prescribing information for complete boxed warning.
Causality screen of the 40 strongest signals
What the badges mean
- Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Likely indication confounding The term appears in the label's indications: reports probably describe the disease being treated (or its progression), not a drug effect. Classic confounding by indication.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 984 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Skin chapped | 99 | 435.1 347.0–545.5ROR 437.9 · χ² 32,045 / p <1e-300 | 309.1 EB05 261.3 · IC025 +6.6 3/3 methods agree | Not in label — unassessed | serious n=44 · 83% consumer | not reported in cached trials |
| Transaminases | 10 | 273.6 138.6–540.0ROR 273.7 · χ² 2,035 / p <1e-300 | 159.0 EB05 92.3 · IC025 +3.2 3/3 methods agree | Labeled adverse reaction exact term | serious n=10 | NCT00374322: 1/1,573 (0.1%) on Lapatinib (serious AE) |
| Nail bed inflammation | 38 | 184.6 131.5–259.0ROR 185.0 · χ² 5,938 / p <1e-300 | 150.2 EB05 114.3 · IC025 +5.2 3/3 methods agree | Labeled (related wording) related wording | serious n=37 | not reported in cached trials |
| Her-2 positive breast cancer | 13 | 136.1 77.0–240.8ROR 136.3 · χ² 1,463 / p <1e-300 | 105.0 EB05 65.3 · IC025 +3.5 3/3 methods agree | Not in label — unassessed | serious n=12 | not reported in cached trials |
| Nasal mucosal disorder | 38 | 94.5 68.0–131.3ROR 94.7 · χ² 3,197 / p <1e-300 | 84.7 EB05 64.4 · IC025 +4.8 3/3 methods agree | Not in label — unassessed | serious n=37 | not reported in cached trials |
| Metastases to skin | 59 | 83.1 63.9–108.0ROR 83.4 · χ² 4,428 / p <1e-300 | 76.4 EB05 61.4 · IC025 +5.1 3/3 methods agree | Not in label — unassessed | serious n=59 | not reported in cached trials |
| Streptococcal sepsis | 57 | 68.2 52.3–88.9ROR 68.4 · χ² 3,526 / p <1e-300 | 63.6 EB05 50.9 · IC025 +4.9 3/3 methods agree | Not in label — unassessed | serious n=57 | NCT00490139: 1/2,056 (0.0%) on Lapatinib (serious AE) |
| Her2 positive breast cancer | 16 | 61.6 37.3–101.7ROR 61.7 · χ² 855 / p 2e-188 | 55.3 EB05 36.1 · IC025 +3.6 3/3 methods agree | Likely indication confounding term in indications; also in warnings | serious n=16 | not reported in cached trials |
| Hormone receptor positive breast cancer | 11 | 59.2 32.4–108.3ROR 59.3 · χ² 548 / p 1e-121 | 52.0 EB05 31.0 · IC025 +3.0 3/3 methods agree | Likely indication confounding term in indications; also in warnings | serious n=11 | not reported in cached trials |
| Paronychia | 174 | 56.9 49.0–66.2ROR 57.6 · χ² 9,120 / p <1e-300 | 54.3 EB05 47.9 · IC025 +5.3 3/3 methods agree | Labeled adverse reaction exact term | serious n=157 | NCT00490139: 1/2,076 (0.0%) on Lapatinib (serious AE) |
| Palmar-plantar erythrodysaesthesia syndrome | 928 | 56.1 52.7–59.8ROR 59.7 · χ² 48,247 / p <1e-300 | 53.9 EB05 51.0 · IC025 +5.6 3/3 methods agree | Not in label — unassessed | serious PRR 54.9 | NCT00490139: 1/2,061 (0.0%) on Lapatinib (serious AE) |
| Metastases to central nervous system | 483 | 53.2 48.7–58.2ROR 54.9 · χ² 23,781 / p <1e-300 | 51.2 EB05 47.4 · IC025 +5.5 3/3 methods agree | Not in label — unassessed | serious PRR 43.0 | NCT00490139: 1/2,056 (0.0%) on Lapatinib (serious AE) |
| Metastases to the mediastinum | 15 | 50.9 30.4–85.2ROR 51.0 · χ² 660 / p 9e-146 | 46.4 EB05 29.8 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious n=15 | not reported in cached trials |
| Onychalgia | 34 | 47.8 33.9–67.2ROR 47.9 · χ² 1,459 / p <1e-300 | 45.1 EB05 33.7 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious n=15 · 79% consumer | not reported in cached trials |
| Breast cancer metastatic | 359 | 47.0 42.4–52.2ROR 48.1 · χ² 15,594 / p <1e-300 | 45.4 EB05 41.6 · IC025 +5.2 3/3 methods agree | Likely indication confounding term in indications; also in warnings | serious PRR 39.3 | not reported in cached trials |
| Lymphangiosis carcinomatosa | 34 | 45.8 32.6–64.4ROR 45.9 · χ² 1,398 / p <1e-300 | 43.3 EB05 32.4 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious n=33 · 94% clinician | not reported in cached trials |
| Pseudomonal sepsis | 56 | 44.6 34.2–58.2ROR 44.8 · χ² 2,268 / p <1e-300 | 42.6 EB05 34.0 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | serious n=56 | not reported in cached trials |
| Nail bed bleeding | 16 | 39.5 24.0–64.9ROR 39.5 · χ² 546 / p 4e-121 | 36.9 EB05 24.1 · IC025 +3.3 3/3 methods agree | Not in label — unassessed | serious n=9 | not reported in cached trials |
| Superior vena cava syndrome | 16 | 36.9 22.4–60.5ROR 36.9 · χ² 509 / p 6e-113 | 34.6 EB05 22.5 · IC025 +3.3 3/3 methods agree | Not in label — unassessed | serious n=16 | not reported in cached trials |
| Nail infection | 37 | 36.0 26.0–49.9ROR 36.1 · χ² 1,193 / p 1e-261 | 34.5 EB05 26.2 · IC025 +4.0 3/3 methods agree | Labeled (related wording) related wording | serious n=22 | NCT00490139: 1/2,061 (0.0%) on Lapatinib (serious AE) |
| Breast neoplasm | 26 | 35.2 23.8–51.9ROR 35.2 · χ² 808 / p 5e-178 | 33.5 EB05 24.0 · IC025 +3.7 3/3 methods agree | Not in label — unassessed | serious n=26 | NCT00490139: 1/2,076 (0.0%) on Lapatinib (serious AE) |
| Radiation necrosis | 14 | 34.2 20.2–58.2ROR 34.3 · χ² 409 / p 3e-91 | 32.1 EB05 20.3 · IC025 +3.1 3/3 methods agree | Not in label — unassessed | serious n=14 | not reported in cached trials |
| Metastases to lymph nodes | 151 | 31.3 26.7–36.8ROR 31.6 · χ² 4,300 / p <1e-300 | 30.5 EB05 26.6 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | serious n=152 | not reported in cached trials |
| Stent occlusion | 11 | 28.3 15.6–51.4ROR 28.3 · χ² 258 / p 3e-58 | 26.5 EB05 15.6 · IC025 +2.7 3/3 methods agree | Not in label — unassessed | serious n=11 | not reported in cached trials |
| Onycholysis | 31 | 27.7 19.4–39.5ROR 27.7 · χ² 755 / p 2e-166 | 26.7 EB05 19.7 · IC025 +3.7 3/3 methods agree | Not in label — unassessed | serious n=20 | not reported in cached trials |
| Joint ankylosis | 11 | 26.6 14.6–48.2ROR 26.6 · χ² 241 / p 1e-54 | 24.9 EB05 14.6 · IC025 +2.6 3/3 methods agree | Not in label — unassessed | serious n=11 | not reported in cached trials |
| Metastases to lung | 202 | 24.2 21.1–27.8ROR 24.5 · χ² 4,392 / p <1e-300 | 23.7 EB05 21.1 · IC025 +4.3 3/3 methods agree | Not in label — unassessed | serious PRR 20.0 | not reported in cached trials |
| Subclavian vein thrombosis | 19 | 23.0 14.6–36.1ROR 23.0 · χ² 371 / p 5e-83 | 22.1 EB05 14.9 · IC025 +3.1 3/3 methods agree | Not in label — unassessed | serious n=19 | NCT00490139: 1/2,076 (0.0%) on Lapatinib (serious AE) |
| Vascular device infection | 74 | 22.6 18.0–28.5ROR 22.7 · χ² 1,484 / p <1e-300 | 22.2 EB05 18.2 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | serious n=74 | not reported in cached trials |
| Skin toxicity | 90 | 22.3 18.1–27.4ROR 22.4 · χ² 1,779 / p <1e-300 | 21.8 EB05 18.3 · IC025 +3.9 3/3 methods agree | Labeled (related wording) related wording | serious n=88 · 90% clinician | not reported in cached trials |
| Dermatitis acneiform | 94 | 21.4 17.5–26.3ROR 21.6 · χ² 1,783 / p <1e-300 | 21.0 EB05 17.7 · IC025 +3.9 3/3 methods agree | Labeled adverse reaction exact term | serious n=52 | NCT00490139: 2/2,056 (0.1%) on Lapatinib (serious AE) |
| Metastases to spine | 52 | 21.4 16.3–28.1ROR 21.5 · χ² 976 / p 2e-214 | 20.9 EB05 16.6 · IC025 +3.7 3/3 methods agree | Not in label — unassessed | serious n=51 | not reported in cached trials |
| Gastrointestinal toxicity | 72 | 21.1 16.7–26.6ROR 21.2 · χ² 1,338 / p 4e-293 | 20.7 EB05 17.0 · IC025 +3.8 3/3 methods agree | Labeled (related wording) related wording | serious n=72 · 93% clinician | NCT00490139: 1/2,056 (0.0%) on Lapatinib (serious AE) |
| Brain cancer metastatic | 10 | 19.9 10.7–37.1ROR 19.9 · χ² 159 / p 1e-36 | 18.4 EB05 9.7 · IC025 +2.3 3/3 methods agree | Not in label — unassessed | serious n=10 | not reported in cached trials |
| Metastases to liver | 247 | 19.4 17.1–22.0ROR 19.7 · χ² 4,237 / p <1e-300 | 19.1 EB05 17.2 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious PRR 16.2 | not reported in cached trials |
| Biliary dilatation | 20 | 18.7 12.0–29.0ROR 18.7 · χ² 312 / p 3e-70 | 18.0 EB05 12.1 · IC025 +2.9 3/3 methods agree | Not in label — unassessed | serious n=20 | not reported in cached trials |
| Nail disorder | 116 | 18.4 15.3–22.1ROR 18.5 · χ² 1,864 / p <1e-300 | 18.1 EB05 15.5 · IC025 +3.8 3/3 methods agree | Labeled adverse reaction exact term | serious n=67 | NCT00490139: 1/2,061 (0.0%) on Lapatinib (serious AE) |
| Invasive ductal breast carcinoma | 36 | 18.2 13.1–25.3ROR 18.2 · χ² 561 / p 3e-124 | 17.8 EB05 13.4 · IC025 +3.3 3/3 methods agree | Not in label — unassessed | serious n=36 | not reported in cached trials |
| Ejection fraction abnormal | 16 | 17.9 10.9–29.3ROR 17.9 · χ² 236 / p 2e-53 | 17.1 EB05 10.7 · IC025 +2.7 3/3 methods agree | Lab value / disease marker | serious n=14 | NCT00490139: 1/2,076 (0.0%) on Lapatinib (serious AE) |
| Breast cancer recurrent | 40 | 17.5 12.8–23.8ROR 17.5 · χ² 597 / p 4e-132 | 17.1 EB05 13.0 · IC025 +3.3 3/3 methods agree | Not in label — unassessed | serious n=39 | not reported in cached trials |
Trial evidence (ClinicalTrials.gov)
✓ Trial adverse-event data found on ClinicalTrials.gov
Largest completed trials with posted results that list Lapatinib as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (12 of 40 signal terms matched).
- NCT00490139 — ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D (N=8381, PHASE3; 530 AE terms posted; arms: Lapatinib Plus Trastuzumab; Trastuzumab Followed by Lapatinib; Lapatinib; Trastuzumab)
- NCT00374322 — Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer (N=3166, PHASE3; 166 AE terms posted; arms: Lapatinib 1500 mg; Placebo)
Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Diarrhoea (diarrhea) | 4,173 | 8.9 8.6–9.1ROR 11.8 · χ² 29,862 / p <1e-300 | 8.8 EB05 8.6 · IC025 +3.1 3/3 methods agree | Labeled — boxed warning exact term | serious PRR 6.8 | NCT00490139: 44/2,056 (2.1%) on Lapatinib (serious AE) |
| Nausea | 1,615 | 2.8 2.7–2.9ROR 3.0 · χ² 1,916 / p <1e-300 | 2.8 EB05 2.7 · IC025 +1.4 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 2.4 | NCT00490139: 7/2,056 (0.3%) on Lapatinib (serious AE) |
| Death | 1,462 | 2.3 2.2–2.4ROR 2.4 · χ² 1,129 / p 7e-248 | 2.3 EB05 2.2 · IC025 +1.1 3/3 methods agree | Outcome field, not a reaction boxed warning mentions mortality | serious PRR 1.9 | NCT00490139: 1/2,056 (0.0%) on Lapatinib (serious AE) |
| Fatigue (tiredness) | 1,306 | 2.3 2.2–2.4ROR 2.4 · χ² 980 / p 2e-215 | 2.3 EB05 2.2 · IC025 +1.1 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 1.9 | NCT00490139: 1/2,056 (0.0%) on Lapatinib (serious AE) |
| Vomiting | 1,209 | 3.5 3.3–3.7ROR 3.7 · χ² 2,214 / p <1e-300 | 3.5 EB05 3.3 · IC025 +1.7 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 3.0 | NCT00490139: 9/2,056 (0.4%) on Lapatinib (serious AE) |
| Rash | 1,062 | 3.3 3.1–3.5ROR 3.5 · χ² 1,766 / p <1e-300 | 3.3 EB05 3.2 · IC025 +1.6 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 3.0 | NCT00490139: 1/2,061 (0.0%) on Lapatinib (serious AE) |
| Disease progression | 1,005 | 11.7 11.0–12.4ROR 12.4 · χ² 9,771 / p <1e-300 | 11.6 EB05 11.0 · IC025 +3.4 3/3 methods agree | Reporting / coding artifact | serious PRR 9.6 | not reported in cached trials |
| Palmar-plantar erythrodysaesthesia syndrome | 928 | 56.1 52.7–59.8ROR 59.7 · χ² 48,247 / p <1e-300 | 53.9 EB05 51.0 · IC025 +5.6 3/3 methods agree | Not in label — unassessed | serious PRR 54.9 | NCT00490139: 1/2,061 (0.0%) on Lapatinib (serious AE) |
| Asthenia (weakness) | 607 | 2.2 2.0–2.4ROR 2.2 · χ² 401 / p 2e-89 | 2.2 EB05 2.0 · IC025 +1.0 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 2.1 | NCT00490139: 4/2,056 (0.2%) on Lapatinib (serious AE) |
| Malignant neoplasm progression | 565 | 7.6 7.0–8.2ROR 7.8 · χ² 3,217 / p <1e-300 | 7.5 EB05 7.0 · IC025 +2.8 3/3 methods agree | Reporting / coding artifact | serious PRR 6.4 | not reported in cached trials |
| Drug ineffective (drug did not work) | 561 | 0.6 0.5–0.6ROR 0.6 · χ² 183 / p 6e-42 | 0.6 EB05 0.5 · IC025 -0.9 PRR-only: not supported by EBGM or IC | Reporting / coding artifact | serious PRR 0.7 | not reported in cached trials |
| Dyspnoea (shortness of breath) | 560 | 1.3 1.2–1.5ROR 1.4 · χ² 51 / p 5e-13 | 1.3 EB05 1.3 · IC025 +0.3 | Labeled adverse reaction exact term | serious PRR 1.3 | NCT00490139: 2/2,056 (0.1%) on Lapatinib (serious AE) |
| Pyrexia (fever) | 527 | 2.1 1.9–2.3ROR 2.1 · χ² 295 / p 2e-66 | 2.1 EB05 1.9 · IC025 +0.9 | Labeled (related wording) related wording | serious PRR 2.0 | NCT00490139: 13/2,056 (0.6%) on Lapatinib (serious AE) |
| Dehydration | 524 | 5.4 4.9–5.8ROR 5.5 · χ² 1,857 / p <1e-300 | 5.3 EB05 4.9 · IC025 +2.3 3/3 methods agree | Not in label — unassessed | serious PRR 4.5 | NCT00490139: 12/2,056 (0.6%) on Lapatinib (serious AE) |
| Decreased appetite (loss of appetite) | 519 | 3.1 2.8–3.3ROR 3.1 · χ² 720 / p 7e-159 | 3.0 EB05 2.8 · IC025 +1.5 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 2.5 | NCT00490139: 3/2,056 (0.1%) on Lapatinib (serious AE) |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Skin chapped — n=99, PRR 435.1
- Nasal mucosal disorder — n=38, PRR 94.5
- Metastases to skin — n=59, PRR 83.1
- Streptococcal sepsis — n=57, PRR 68.2 (also seen in trial arm)
- Palmar-plantar erythrodysaesthesia syndrome — n=928, PRR 56.1 (also seen in trial arm)
- Metastases to central nervous system — n=483, PRR 53.2 (also seen in trial arm)
- Onychalgia — n=34, PRR 47.8
- Lymphangiosis carcinomatosa — n=34, PRR 45.8
- Pseudomonal sepsis — n=56, PRR 44.6
- Breast neoplasm — n=26, PRR 35.2 (also seen in trial arm)
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Lapatinib?
In FDA FAERS, the most frequently co-reported reaction terms for Lapatinib are diarrhoea, nausea, fatigue, vomiting, rash, palmar-plantar erythrodysaesthesia syndrome. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Lapatinib have an FDA boxed warning?
Yes. The current FDA label carries a boxed warning: HEPATOTOXICITY Hepatotoxicity has been observed in clinical trials and postmarketing experience. The hepatotoxicity may be severe and deaths have been reported. Causality of the deaths is uncertain [see Warnings and Precautions (5.2)]. WARNING: HEPATOTOXICITY See full prescribing information for complete boxed warning.
Do FAERS signals prove that Lapatinib causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 50d0dd0c-7682-43d0-aa1b-ca26e9181aee, effective 20250610; matched on
openfda.generic_name.exact:"LAPATINIB") - Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,024 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
LAPATINIB, results-bearing studies sorted by enrollment)
Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.